Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Remus Pharmaceuticals Ltd

Pharmaceuticals & Biotechnology | Small Cap

Remus Pharmaceuticals Ltd Health Insights
Health Score : 5.31Health Score : 5.31

Remus Pharmaceuticals shows a mixed financial picture. The company demonstrates significant strengths in solvency, growth, and coverage ratios, suggesting a solid capital structure and promising expansion. However, it struggles with liquidity, efficiency, financial metrics, and profitability, indicating potential challenges in short-term financial management and revenue generation. While the company's solvency is strong, its ability to convert assets into profits and manage short-term obligations appears weak. The healthcare industry's dynamic nature means Remus Pharmaceuticals needs to address these weaknesses to maintain a competitive edge and ensure long-term sustainability. The company shows promise with interest coverage, suggesting it can comfortably handle its debt obligations. The company shows promise with growth in operating profit, EPS, and assets, which could translate to enhanced shareholder value if properly managed. However, the low scores in liquidity, efficiency and profitability need to be addressed for balanced financial health.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Remus Pharmaceuticals Ltd Health Insights
Health Score : 5.31Health Score : 5.31

Remus Pharmaceuticals shows a mixed financial picture. The company demonstrates significant strengths in solvency, growth, and coverage ratios, suggesting a solid capital structure and promising expansion. However, it struggles with liquidity, efficiency, financial metrics, and profitability, indicating potential challenges in short-term financial management and revenue generation. While the company's solvency is strong, its ability to convert assets into profits and manage short-term obligations appears weak. The healthcare industry's dynamic nature means Remus Pharmaceuticals needs to address these weaknesses to maintain a competitive edge and ensure long-term sustainability. The company shows promise with interest coverage, suggesting it can comfortably handle its debt obligations. The company shows promise with growth in operating profit, EPS, and assets, which could translate to enhanced shareholder value if properly managed. However, the low scores in liquidity, efficiency and profitability need to be addressed for balanced financial health.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

38.15

Neutral

Industry Median

28.62

Neutral
Neutral

Small Cap Median

27.17

Neutral

P/E RATIO

25.48

P/B RATIO

2.68

Neutral

Industry Median

3.17

Neutral
Neutral

Small Cap Median

2.62

Neutral

P/S RATIO

1.08

Highly Undervalued

Industry Median

3.42

Highly Undervalued
Undervalued

Small Cap Median

2.55

Undervalued

Others

Neutral

PEG RATIO

0.00

Neutral
Overvalued

EV/EBITDA RATIO

14.55

Overvalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹799.95 as on Jun 20, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 6.00

The company demonstrates strong growth in operating profit, EPS, and assets, signaling promising expansion and potential for enhanced shareholder value. However, low revenue and net income growth rates indicate areas needing attention to ensure balanced and sustainable growth. These strengths suggest a positive trajectory for the company's future. The company's growth in operating profit, EPS, and assets can lead to increased shareholder value.

PoorRevenue Growth RatePoor
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
ExcellentAsset Growth RateExcellent
PoorNet Income Growth RatePoor
Growth RatiosMar 2024Mar 2025Mar 2026
Revenue Growth Rate191.0837.74
Operating Profit Growth Rate58.6223.91
Earnings Per Share (EPS) Growth39.2927.39
Asset Growth Rate30.0333.72
Net Income Growth Rate58.3321.05
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 4.20

The company's financial ratios present a mixed picture. While capital expenditures management is strong, low adjusted EPS, cash EPS, book value per share, and dividend per share indicate areas needing improvement. These factors suggest a need to enhance overall financial performance. The weighted average calculation highlights the impact of the stronger capital expenditure metric.

PoorAdjusted Earnings Per Share (Adjusted EPS)Poor
WeakCash Earnings Per Share (Cash EPS)Weak
WeakBook Value Per ShareWeak
PoorDividend Per Share (DPS)Poor
ExcellentCapital Expenditures (CapEx)Excellent
Financial RatiosMar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)277.678.6545.98
Cash Earnings Per Share (Cash EPS)25066.6740.83
Book Value Per Share1570426.67292.5
Dividend Per Share (DPS)0.710.740.63
Capital Expenditures (CapEx)123.713.7
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 4.60

The company's profitability ratios are mixed. Strong ROCE and ROA are offset by low gross profit, operating, and net margins, indicating potential weaknesses in revenue generation and cost control. This suggests a need to improve overall profitability. The weighted average calculation highlights the impact of the stronger ROCE and ROA values.

PoorGross Profit MarginPoor
ExcellentReturn on Capital Employed (ROCE)Excellent
PoorReturn on Equity (ROE)Poor
GoodReturn on Assets (ROA)Good
PoorOperating MarginPoor
PoorNet MarginPoor
Profitability RatiosMar 2024Mar 2025Mar 2026
Gross Profit Margin13.157.16.32
Return on Capital Employed (ROCE)18.442017
Return on Equity (ROE)15.2914.8413.11
Return on Assets (ROA)8.7110.629.84
Operating Margin13.627.426.67
Net Margin11.276.135.39
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 4.67

The company's efficiency ratios present a mixed picture. While days sales in inventory and receivable days suggest effective management, low turnover ratios across fixed assets, inventory, receivables, and capital indicate potential issues in asset utilization. These inefficiencies could hinder the company's ability to maximize profits and returns. The weighted average calculation highlights the impact of current inefficiencies.

PoorFixed Asset Turnover RatioPoor
PoorInventory Turnover RatioPoor
PoorReceivables Turnover RatioPoor
ExcellentDays Sales in Inventory RatioExcellent
ExcellentReceivable DaysExcellent
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio15.2138.7547.44
Inventory Turnover Ratio4.312.1512.9
Receivables Turnover Ratio1.845.566.89
Days Sales in Inventory Ratio84.8830.0428.29
Receivable Days19865.6552.98
Capital Turnover Ratio1.312.372.37
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 6.80

The company demonstrates a strong ability to cover its interest expenses but shows weakness in equity dividend coverage. While the interest coverage ratio suggests financial stability, the lack of equity dividend coverage may concern shareholders. This indicates a need to balance debt obligations with shareholder returns. The weighted average calculation highlights the disproportionate impact of interest coverage on the overall score.

ExcellentInterest Coverage RatioExcellent
PoorEquity Dividend Coverage RatioPoor
Coverage RatiosMar 2024Mar 2025Mar 2026
Interest Coverage RatioN/A4860
Equity Dividend Coverage Ratio2533.3350
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company exhibits a strong solvency position, suggesting a stable capital structure and a low risk of financial distress. This indicates a healthy balance between debt and equity, enabling the company to manage its long-term obligations effectively. This stability provides a solid foundation for future growth and investment. However, it is important to maintain this balance and avoid excessive reliance on debt.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2024Mar 2025Mar 2026
Debt Ratio0.030.020.03
Debt to Equity Ratio0.030.020.03
Equity Ratio0.970.980.97
Debt To Asset Ratio0.020.010.02
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 2.00

The company's liquidity position is weak, suggesting potential difficulties in meeting its short-term obligations. This could hinder its ability to invest in growth opportunities and respond to unexpected financial challenges. While the company may have sufficient assets, their ability to convert those assets quickly into cash is questionable. The weighted average calculation, heavily influenced by recent performance, amplifies the impact of current liquidity struggles.

PoorCurrent RatioPoor
PoorQuick RatioPoor
PoorCash RatioPoor
PoorOperating Cash Flow RatioPoor
Liquidity RatiosMar 2024Mar 2025Mar 2026
Current Ratio1.271.351.27
Quick Ratio1.011.040.94
Cash Ratio0.080.050.06
Operating Cash Flow Ratio0.010.040.08
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 17 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Accent Microcell Ltd7.9624.25Neutral57.0018.2844.00
2Lincoln Pharmaceuticals Ltd7.3114.01Neutral98.0043.8888.00
3NGL Fine Chem Ltd6.9839.22Overvalued73.0067.3948.00
4Medico Remedies Ltd6.6137.70Overvalued17.001.5813.00
5Kilitch Drugs (India) Ltd6.6121.54Neutral37.009.2730.00
6Kopran Ltd6.6025.82Neutral62.006.3026.00
7SMS Lifesciences India Ltd6.5921.20Undervalued45.0070.6819.00
8Infinium Pharmachem Ltd6.4226.90Neutral22.006.4314.00
9Sakar Healthcare Ltd5.8158.66Highly Overvalued69.0013.7030.00
10Medicamen Biotech Ltd5.7332.19Neutral20.006.9410.00
11Albert David Ltd5.63-272.47Neutral5.00-2.62-1.00
12Zim Laboratories Ltd5.4141.96Neutral30.001.116.00
13Remus Pharmaceuticals Ltd5.3125.48Neutral57.0020.9746.00
14Ind-Swift Laboratories Ltd4.9539.28Neutral45.004.8941.00
15Venus Remedies Ltd4.8323.37Neutral147.0074.30103.00
16Wanbury Ltd4.6528.62Neutral88.0018.9343.00
17Nectar Lifescience Ltd3.83-2.67Neutral-59.00-2.95-293.00
Management Assessment Summary
OrangeBalanced Management

The management of Remus Pharmaceuticals shows mixed performance. Strong sales growth is evident, with a TTM growth of 192%. However, the operating profit margin (OPM) has declined from 13% to 7%, suggesting operational inefficiencies. The company's ROCE is 41.31, and ROE is 33.24, indicating efficient use of capital and shareholder funds. Promoter holding is consistently high at around 70%, indicating confidence.

Category Metric Value Assessment
PROS Sales Growth (TTM) 192% Aggressive revenue scaling
ROCE 41.31 Efficient use of capital
ROE 33.24 Efficient use of shareholder funds
Promoter Holding ~70% High confidence
CONS Operating Profit Margin 7% Declining profitability
AverageFinancial Performance & GrowthAverage
ExcellentCapital Efficiency & ReturnsExcellent
AverageFinancial Health & PrudenceAverage
ExcellentShareholding & Ownership StructureExcellent
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

The risk assessment for Remus Pharmaceuticals reveals a moderate level of concern. While the company shows strong sales growth and high promoter holding, there are risks associated with declining operating profit margins and increasing borrowings. The decrease in OPM from 13% to 7% indicates potential operational inefficiencies. The increase in borrowings from ₹12 Cr to ₹23 Cr warrants monitoring.

AverageSegment performance volatilityAverage
AverageForeign exchange or interest rate exposureAverage
AverageRegulatory compliance cost trendsAverage
01.

Segment performance volatility

02.

Foreign exchange or interest rate exposure

03.

Regulatory compliance cost trends

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10807.98Bearish
  3. SMA 20784.60Bullish
  4. SMA 50746.47Bullish
  5. EMA 10798.50Bullish
  6. EMA 20788.01Bullish
  7. EMA 50761.24Bullish
  8. DEMA 10805.67Bearish
  9. DEMA 20809.69Bearish
  10. DEMA 50789.76Bullish
  11. TEMA 10801.42Bearish
  12. TEMA 20809.84Bearish
  13. TEMA 50812.33Bearish
  14. MACD15.44Bearish
  15. ADX32.94Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI58.84Neutral
  3. CCI45.60Neutral
  4. ROC 9-2.20Bearish
  5. ROC 142.96Bullish
  6. ROC 255.68Bullish
  7. Stoch K62.69Neutral
  8. Stoch D63.37Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper838.27Neutral
  3. BB Middle784.60Neutral
  4. BB Lower730.93Neutral
  5. ATR9.99Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI78.70Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10793.95Bullish
  3. SMA 20777.61Bullish
  4. SMA 50730.78Bullish
  5. EMA 10793.07Bullish
  6. EMA 20774.87Bullish
  7. EMA 50750.12Bullish
  8. DEMA 10809.76Bearish
  9. DEMA 20805.21Bearish
  10. DEMA 50766.57Bullish
  11. TEMA 10807.27Bearish
  12. TEMA 20816.56Bearish
  13. TEMA 50785.37Bullish
  14. MACD22.84Bullish
  15. ADX37.08Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI60.62Neutral
  3. CCI79.46Neutral
  4. ROC 96.67Bullish
  5. ROC 144.05Bullish
  6. ROC 2516.80Bullish
  7. Stoch K64.34Neutral
  8. Stoch D70.03Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper828.25Neutral
  3. BB Middle777.61Neutral
  4. BB Lower726.97Neutral
  5. ATR14.94Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI66.40Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10781.15Bullish
  3. SMA 20736.97Bullish
  4. SMA 50757.15Bullish
  5. EMA 10776.54Bullish
  6. EMA 20755.71Bullish
  7. EMA 50740.43Bullish
  8. DEMA 10804.95Bearish
  9. DEMA 20778.43Bullish
  10. DEMA 50761.95Bullish
  11. TEMA 10813.61Bearish
  12. TEMA 20801.35Bearish
  13. TEMA 50N/AN/A
  14. MACD20.34Bullish
  15. ADX29.50Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI62.12Neutral
  3. CCI100.01Overbought
  4. ROC 94.58Bullish
  5. ROC 1417.65Bullish
  6. ROC 2513.48Bullish
  7. Stoch K84.67Overbought
  8. Stoch D90.66Overbought
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper831.77Neutral
  3. BB Middle736.97Neutral
  4. BB Lower642.18Neutral
  5. ATR23.13Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI74.95Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (22)
  1. IndicatorValueSignal
  2. SMA 10739.66Bullish
  3. SMA 20731.41Bullish
  4. SMA 50718.36Bullish
  5. SMA 100686.14Bullish
  6. SMA 200719.06Bullish
  7. EMA 10759.87Bullish
  8. EMA 20746.22Bullish
  9. EMA 50724.57Bullish
  10. EMA 100714.46Bullish
  11. EMA 200747.81Bullish
  12. DEMA 10783.98Bullish
  13. DEMA 20762.22Bullish
  14. DEMA 50751.59Bullish
  15. DEMA 100705.68Bullish
  16. DEMA 200664.35Bullish
  17. TEMA 10805.43Bearish
  18. TEMA 20766.55Bullish
  19. TEMA 50769.84Bullish
  20. TEMA 100749.85Bullish
  21. TEMA 200660.36Bullish
  22. MACD14.05Bullish
  23. ADX18.76Weak Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI59.73Neutral
  3. CCI149.71Overbought
  4. ROC 1412.68Bullish
  5. ROC 2510.94Bullish
  6. Stoch K87.38Overbought
  7. Stoch D88.83Overbought
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper811.19Neutral
  3. BB Middle731.41Neutral
  4. BB Lower651.63Neutral
  5. ATR37.95Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI64.60Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Trend Indicators (10)
  1. IndicatorValueSignal
  2. SMA 20681.09Bullish
  3. SMA 50744.90Bearish
  4. EMA 20704.32Bearish
  5. EMA 50757.79Bearish
  6. DEMA 20694.42Bullish
  7. DEMA 50663.85Bullish
  8. TEMA 20728.68Bearish
  9. TEMA 50645.81Bullish
  10. MACD-3.37Bullish
  11. ADX20.05Weak Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI47.46Neutral
  3. CCI-40.19Neutral
  4. ROC 1413.08Bullish
  5. ROC 25-5.44Bearish
  6. Stoch K33.21Neutral
  7. Stoch D44.50Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper800.17Neutral
  3. BB Middle681.09Neutral
  4. BB Lower562.00Neutral
  5. ATR86.38Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI81.20Overbought

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 6671.08Bullish
  3. SMA 12746.14Bearish
  4. SMA 24960.76Bearish
  5. EMA 6692.66Bullish
  6. EMA 12755.34Bearish
  7. EMA 24799.08Bearish
  8. DEMA 6651.03Bullish
  9. DEMA 12650.96Bullish
  10. DEMA 24N/AN/A
  11. TEMA 6678.88Bullish
  12. TEMA 12622.66Bullish
  13. TEMA 24N/AN/A
  14. MACDN/AN/A
  15. ADX26.78Strong Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI58.32Neutral
  3. CCIN/AN/A
  4. ROC 25-24.43Bearish
  5. ROC 50N/AN/A
  6. Stoch KN/AN/A
  7. Stoch DN/AN/A
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper1389.61Neutral
  3. BB Middle915.42Neutral
  4. BB Lower441.24Neutral
  5. ATR198.06High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI46.68Neutral